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This research was carried out to detect the presence of Chlamydia in pregnant women and 
gynaecologic patients in the North-central geopolitical zone of Nigeria. Blood samples were collected 
and analysed by ELISA techniques. The blood samples were also screened for HIV infection. A sero-
prevalence of 59.0% was recorded for the study area. The sero-prevalence was higher among the 
gynaecologic patients (62.0%) than the pregnant women (57.5%). The difference was statistically 
significant (P = 0.0001). Of the four centers chosen for the study, the Federal Capital Territory (Abuja) 
had the highest prevalence (84.7%), while Niger State had the least (28.7%). The difference was also 
statistically significant (P<0.0001). The prevalence rate of HIV among the participants in the study 
center was found to be 17.2%. Abuja had the highest prevalence rate of 24.6%, followed by Benue, 
16.7%, then Kogi, 12.0% and finally, Niger, 4.7%. Chlamydia was found to be associated with HIV 
(p<0.0001). The sero-prevalence of chlamydia in the North-Central zone of Nigeria was found to be 
high.  Chlamydia was found to be correlated with HIV in the study area and may have contributed to the 
zone emerging with the highest HIV prevalence in the country. For an infection that is largely 
asymptomatic but has devastating effects on populations, only a preventive approach would have 
beneficial effects in controlling the disease and its effects on women’s health in the country. 
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INTRODUCTION 
Chlamydial infection is the most common 
curable bacterial sexually transmitted disease 
(CDC, 2006; WHO, 2011). The incidence of 
chlamydial infections in women has increased 
dramatically from 79 to 467 per 100,000 
between 1987 and 2003 (Sexually transmitted 
disease surveillance, 2004). According to the 
World Health Organization (WHO, 2011), 101 
million chlamydial infections are detected 
annually worldwide. In the U.S. the Centres for 
Disease Control and Prevention (CDC) 
estimates that 2.8 million people are infected 
each year (CDC, 2006). In some parts of the 
third-world countries, more than 90 per cent of 
the population is infected (Gomes et al., 2007).  
Chlamydial infection is caused by Chlamydia 
trachomatis, a coccoid bacillus closely related 
to Gram negative bacteria (Cheesbrough, 
2000). Chlamydia trachomatis belongs to the 
genus Chlamydia which includes organisms 
previously called the Psittacosis 
Lymphogranuloma venerum Trachoma group 
(PLT) or the TRIC (TRachoma Inclusion 
Conjunctivitis group) (Mackie & Mac Cartney, 
1989). 
 
Chlamydia trachomatis has 15 immunotypes 
(serotypes) viz; A-C which cause trachoma 
(chronic conjunctivitis endemic in Africa and 
Asia), D-K, which cause genital tract infection 
and L1-L3 responsible for lymphogranuloma 
venerum (associated with genital ulcer disease 
in tropical countries). Chlamydia trachomatis 
serovars D-K cause curable sexually 
transmitted disease called Chlamydia (CDC, 
2006). The disease which arises from the 
infection of the lower genital tract is one of the 
most prevalent sexually transmitted diseases in 
the world (Gerbase et al., 1998; Beagley and 
Timms, 2000). It is usually asymptomatic, in 
fact 50% of men and 80% of women are 
asymptomatic, and for this reason it is referred 
to as silent disease (Gaydos et al., 1998; CDC, 
2006; Ward et al., 2007). In cases where 
symptoms are present they may last only a few 
days and may not be noticed or considered 
significant (Kidshealth, 2006). Clinical 
symptoms in women, where present include 
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vaginal discharge, dysuria, easily induced 
endocervical bleeding, irregular menstruation or 
intermenstrual bleeding, dyspareunia, lower 
abdominal pain, genital itching, increased 
urination frequency and sore in the vagina 
(CDC, 2006; Al-Mutairi et al., 2007). 
 
Chlamydia is one of the non – ulcerative 
sexually transmitted infections which elicit 
localised inflammations and immune responses 
characterised by the infiltration and 
accumulation of immune cells expressing CD4 
surface proteins essential for the binding of HIV 
prior to entry, thus also facilitating the entry of 
HIV (Altes et al., 2002; Joyee et al., 2005; 
Wodarz and Hamer 2007). In a study 
conducted in the South- Eastern part of Nigeria 
by Nwaguma et al. 2009, it was found out that 
the prevalence of C. trachomatis infection 
observed in the HIV – seropositive subjects 
(50%) was much higher than the prevalence in 
the HIV-seronegative subjects (17.6%) 
(Nwaguma et al., 2009). 
 
Chlamydia, if left untreated can persist for at 
least 15 months (Mc Cormack et al., 1979) and 
can have potentially serious lifetime 
consequences which include pelvic 
inflammatory disease (PID) (Stamm et al., 
1984, Land, 2010). PID is a general term that 
refers to infection and inflammation of the upper 
genital tract in women. It can affect the uterus 
(womb), fallopian tubes, ovaries and other 
organs related to reproduction (Moss, 2001). In 
USA, approximately 20-30 per cent of PID 
cases have been attributed to C. trachomatis 
(Soper, 2010). The incidence rates of PID in 
Nigeria vary between 0.28 and 4.4% of 
deliveries (Iloabachi, 1990). Sequelae of PID 
include ectopic pregnancy and tubal infertility 
(Buchan et al., 1993). The risk of developing 
sequelae is dependent on the number of PID 
episodes (Westrom, 1994). Epidemiological 
studies have shown that sexually transmitted 
pathogens, including non-ulcerative agents 
such as C. trachomatis, may serve as biological 
cofactors for human immunodeficiency virus 
(HIV) seroconversion (Plummer et al., 1991; 
Laga et al., 1993; Grosskurth et al., 1995). 
However, basic data, such as the incidence and 
prevalence of many sexually transmitted 
diseases (STDs), which are necessary for 
obtaining estimates of their impact on sexual 
transmission of HIV, are relatively scarce in 
developing countries. In many areas, diagnosis 
of C. trachomatis genital infection is only 
performed in selected populations and is often 
based on the presence of clinical symptoms. 
Considering the high rate of asymptomatic 
chlamydial infection, particularly in women, a 
substantial “silent” or undetected epidemic of C. 
trachomatis infections could put this population 
at significant risk for HIV infection. A reliable 
epidemiological data is needed to determine the 
prevalence rate of the disease in the 
populations which will help in devising an 
effective chlamydia control program. It is in view 
of the above that this research work was carried 
out to detect the presence of Chlamydia in 
pregnant women and gynaecologic patients in 
the North-central geopolitical zone of Nigeria 
and to check the rate of occurrence of 
Chlamydia – HIV co-infection. 
 
METHODOLOGY 
By simple random sampling method, three 
states (Benue, Kogi and Niger) and the Federal 
Capital Territory were selected from the North-
Central geo-political zone. The Federal Medical 
Centers, Makurdi, and Kogi, the National 
Hospital, Abuja and the General Hospital Minna 
were chosen for the study. The study groups 
comprised 400 pregnant women and 200 
gynaecologic patients attending the 
gynecological clinics for PID, infertility and 
ectopic pregnancy. Only those who had not 
been on antibiotics (azithromycin, erythromycin, 
doxycycline, or tetracycline) in the past three 
months before sampling were included in the 
study. Each subject gave her consent and the 
study was approved by the Ethical Committees 
of the Hospitals. Data were analyzed using Chi-
square test and P ≤ 0.05 was considered 
statistically significant.  
 
Blood sample collection 
Five (5) ml of blood sample was collected from 
each participant by venepuncture and stored in 
venoject vacutaneers and allowed to clot. The 
sera were separated by spinning the blood in a 
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centrifuge at 3000 rpm and stored at -20o C till 
use. 
 
Anti – Chlamydia trachomatis ELISA 
Chlamydia trachomatis IgG ELISA test kit by 
DIAGNOSTIC AUTOMATION, INC, Calabasas 
was used. It employs the LGV type 2 broadly 
reacting antigen of Chlamydia trachomatis. It 
detects Chlamydia trachomatis, Chlamydia 
psittaci and Chlamydia pneumonia (TWAR) 
antibodies. It was performed according to the 
manufacturer’s instruction. 
 
Test for HIV 
Determine kits for the test of HIV1/2 
manufactured by Alere Medical Co. Japan were 
used to screen the blood samples. It is an in 
vitro, visually read, qualitative immunoassay for 
the detection of antibodies to HIV-1/2 in human 
serum, plasma or whole blood. The Determine 
positive samples were further tested using HIV 
1/2 STAT-PAK DIPSTICK kit manufactured by 
Chembio Diagnostic Systems, INC, USA. Both 




The study population was made up of two 
groups, pregnant women and gynaecologic 
patients. Of the 400 pregnant women tested, 
230 were positive for Chlamydia IgG with a 
prevalence rate of 57.5% while 124 out of the 
200 gynaecologic patients tested positive giving 
a prevalence rate of 62.0%. The results are as 
shown in Table 1.  
 
The six hundred blood samples constituted one 
hundred and fifty (150) from each of the Federal 
Capital Territory (Abuja), Benue, Kogi and Niger 
States. Of the 150 samples from each study 
center, 100 were from pregnant women and 50 
from gynaecologic patients. Of the 150 samples 
assayed from each of the centers, 127, 107, 77 
and 43 samples were found positive for the 
Federal Capital Territory (Abuja), Benue, Kogi 
and Niger States respectively giving prevalence 
rates of 84.7%, 71.3% 51.3% and 28.7% 
respectively. The sero-prevalence of Chlamydia 
IgG antibodies in parts of the North-Central 
Nigeria is shown in Table 2. 
 
All the participants in the study groups were 
also screened for HIV to determine the 
relationship between Chlamydia and HIV in 
them. Of the 600 samples tested for HIV, 103 
were positive giving a prevalence rate of 17.2%. 
Abuja had the highest prevalence rate of 24.6% 
(37 in 150), followed by Benue, 16.7%, (25 in 
150) then Kogi, 12.0% (18 in 150) and finally, 
Niger, 4.7% (07 in 150). The results of HIV 
prevalence in the North Central are shown in 
Table 3.  
As for relationship between Chlamydia and HIV, 
61 subjects tested positive for both Chlamydia 
and HIV, 293 were positive for Chlamydia only, 
while 18 had only HIV. Results are shown in 
Table 4. 
 
Table 1: Seroprevalence of Chlamydia IgG antibodies in parts of the North-Central Nigeria based on the 
study groups 
Group No. Screened No. Pos % Prevalence 
Pregnant 400 230 57.5 
Gynaecologic 200 124 62.0 
Total  600 354 59.0 
X2 =1.11  P= 0.292 
 
Table 2: Seroprevalence of Chlamydia IgG antibodies in parts of the North-Central Nigeria 
Part No. Screened No. Positive % Prevalence 
Abuja 150 127 84.7 
Benue 150 107 71.3 
Kogi 150 77 51.3 
Niger 150 43 28.7 
X2 = 111, (P<0.0001) 
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Table 3: Prevalence of HIV 1/2 among the study participants in parts of the North-central 
 No. Screened No. Positive % prevalence 
Abuja 150 37 24.6 
Benue 150 25 16.7 
Kogi 150 18 12.0 
Niger 150 07 4.7 
Total  600 87 14.5 
  
Table 4: Relationship between Chlamydia and HIV in parts of the North Central 
 No. Screened Positive %prevalence 
All Chlamydia 600 354 59.0 
All HIV 600 79 13.2 
Chlamydia only 600 293 48.8 
HIV only 600 18 3.0 
Chlamydia and HIV 600 61 10.2 
X2 = 779.7   p < 0.0001 
 
DISCUSSION 
The seroprevalence of Chlamydia IgG antibody 
in parts of the North central Nigeria was found 
to be 59.0% in this study. This high prevalence 
is in line with the report by (CDC) in 2005 that in 
the United States, chlamydial genital infection is 
the most frequently reported infectious disease, 
and the prevalence is highest in persons aged 
<25 years (CDC, 2005). It is also similar to the 
findings of Mawak et al., 2011 and Dibua et al., 
2013 which was 56.1% among gynaecologic 
clinic attendees in Jos and Nsukka respectively. 
A 51.0% prevalence among pregnant and non-
pregnant women and their spouses attending 
pre and antenatal clinic in the College of 
Medicine of the University of Lagos has been 
reported (Okoror et al., 2000). A slightly lower 
prevalence of 40.7% of C. trachomatis has also 
been reported from the South-Eastern part of 
Nigeria (Okoror et al., 2007). Other lower 
prevalences of 38.3% in Zaria (Tukur et al., 
2006) and 13.3% in Benin City (Isibor et al., 
2005) have also been reported. 
 
The high prevalence found in this part of the 
country in this study can be considered as an 
evidence of endemicity in the population and 
this may be due to the fact that Chlamydia 
infections usually present with no clear cut 
symptoms and are as a result left untreated or 
mistaken for other infections such as 
gonorrhoea. This often leads to serious 
sequelae such as pelvic inflammatory disease 
(PID), endometrirtis, salpingitis, ectopic 
pregnancy and infertility (Mabey et al., 1992).  
 
Other factors that could be attributable to the 
high prevalence and endemicity are 
sociocultural inhibition that prevents women 
from reporting sexual symptoms and non-
availability of facility to detect the causative 
agent (Chlamydia trachomatis) in many health 
care centres in this part of the world (Okonofua 
et al., 1995). The high prevalence could have 
also been caused by the high prevalence of 
HIV-AIDS in the area. According to the 
Technical Report of the 2010 National HIV 
Sero-prevalence Sentinel Survey, the North-
central geopolitical zone had the highest 
prevalence rate of AIDS and studies have 
shown the association between the two 
infections (chlamydia and HIV) such that the 
presence of one facilitates that of the other. 
Genital Chlamydia infection has been linked to 
an increasing risk for acquisition of HIV disease 
(Laga et al., 1993; Ho et al., 1995; Brunham, et 
al., 1996; Stamm, 1999; Joyee, et al., 2005) 
while on the other hand, immunosuppresion 
due to HIV may lead to more severe Chlamydia 
disease condition like PID in those who are 
infected with Chlamydia trachomatis (Thomas, 
et al., 2002). Thus early diagnosis and 
treatment of Chlamydia infections is important 
to prevent HIV risk and devastating clinical 
consequence. The two infections (Chlamydia 
and HIV infections) have also being reported to 
have common risk factors, for instance, Joyee, 
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et al., (2005) reported that both HIV and 
Chlamydia are significantly associated with 
some risk factors such as multiple sexual 
partners.  
 
The possible relationships between HIV 
infection and Chlamydia trachomatis are that 
the invasive intracellular pathogenesis of 
Chlamydia trachomatis can cause substantial 
damage to the genital epithelial layer which 
may facilitate HIV infection (Hitchcock, 1999) 
and immunological changes due to HIV 
infection may favor Chlamydia trachomatis 
(Debattista et al., 2002). Chlamydia is one of 
the non – ulcerative sexually transmitted 
infections which elicit localised inflammations 
and immune responses characterised by the 
infiltration and accumulation of immune cells 
expressing CD4 surface proteins essential for 
the binding of HIV prior to entry, thus also 
facilitating the entry of HIV (Altes et al., 2002; 
Joyee et al., 2005; Wodarz and Hamer, 2007). 
 
The results of this study also showed that the 
prevalence of Chlamydia was slightly higher 
among gynaecologic cases (62.0%) than in the 
pregnant women (57.5%). This is similar to an 
earlier report in Delta State by Omo-Aghoja et 
al. (2007), that the prevalence of serum 
Chlamydia antibody was significantly higher in 
cases (65.8%) (tubal infertility) compared with 
controls (pregnant women) (17.3%; P < 0.01).  
Although it is not recommended for the 
diagnosis of lower genital tract infections, or for 
screening in asymptomatic patients, serological 
testing has been shown to be useful for 
diagnosing LGV, neonatal pneumonia and 
upper genital tract infections, and for the 
evaluation of tubal-factor infertility (Persson, 
2002; Be´be´ar and de Barbeyrac, 2009).  
 
Conclusively, the sero-prevalence of chlamydia 
in the North-Central zone of Nigeria was found 
to be high and it was found to be associatedted 
with HIV in the study area and may have 
contributed to the zone emerging with the 
highest HIV prevalence in the Country. Future 
studies are required to investigate the 
genotypes of chlamydia in circulation in the 
study population and to investigate the role of 
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